MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Mindwalk Holdings Corp..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.635 2.7 million, and an increase to 65% 00:00:04.635 -- 00:00:08.497 growth margin for continuing operations. 00:00:08.879 -- 00:00:13.944 Across pharma and biotech, AI now sits near the center of pipeline strategy 00:00:13.944 -- 00:00:19.089 and R&D planning. Recent surveys show AI in active use 00:00:19.089 -- 00:00:24.915 at scale with roughly two-thirds of life science professionals using AI in 2024, 00:00:24.915 -- 00:00:30.158 up from just over half the prior year, and a large 00:00:35.131 -- 00:00:39.613 data volumes continue to accelerate. 00:00:39.815 -- 00:00:44.978 Global data creation is estimated at roughly 180 zettabytes 00:00:44.980 -- 00:00:46.922 in 2025, 00:00:46.922 -- 00:00:52.087 with genomics among the fastest growing contributors and genomics data capacity 00:00:52.087 -- 00:00:55.070 already measured in tens of exabytes. 00:00:55.070 -- 00:01:00.815 Data generation now runs ahead of the world's ability to extract stable biological signals 00:01:00.815 -- 00:01:04.662 and convert them into actionable decisions. 00:01:04.662 -- 00:01:09.949 Investments reflect this shift. Independent market analyses point to sustained 00:01:09.949 -- 00:01:15.256 double-digit annual growth for AI-enabled R&D platforms, including AI-driven 00:01:15.256 -- 00:01:21.605 drug discovery, informatics software, cloud-based infrastructure, and life science analytics. 00:01:21.605 -- 00:01:26.852 Large pharma, major technology firms, and specialized platforms 00:01:26.852 -- 00:01:31.953 are all expanding AI capacity. Once an organization secures an advantage 00:01:31.953 -- 00:01:37.019 in data quality, model design, and biological grounding, that advantage 00:01:37.019 -- 00:01:38.700 compounds. 00:01:38.700 -- 00:01:43.926 Those that f...